The role of PGC1α in cancer metabolism and its therapeutic implications

Molecular Cancer Therapeutics

Volumn 15, Issue 5, 2016, Pages 774-782

  Tan, Zheqiong ^a,b   Luo, Xiangjian ^a,b   Xiao, Lanbo ^a,b   Tang, Min ^a,b   Bode, Ann M ^c   Dong, Zigang ^c   Cao, Ya ^a,b  

^a Central South University   (China)

^b CENTRAL SOUTH UNIVERSITY   (China)

^c UNIVERSITY OF MINNESOTA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN RECEPTOR; ESTROGEN RECEPTOR ALPHA; MICROPHTHALMIA ASSOCIATED TRANSCRIPTION FACTOR; MYC PROTEIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA COACTIVATOR 1ALPHA; PROMYELOCYTIC LEUKEMIA PROTEIN; PROTEIN P53; REACTIVE OXYGEN METABOLITE; SIRTUIN 1;

AEROBIC METABOLISM; AMINO TERMINAL SEQUENCE; APOPTOSIS; AUTOPHAGY; BREAST CANCER; CANCER CHEMOTHERAPY; CARBOXY TERMINAL SEQUENCE; CELL FATE; CELL METABOLISM; CELL PROLIFERATION; CELL STRESS; CELL SURVIVAL; CIRCULATING TUMOR CELL; DEACETYLATION; FATTY ACID METABOLISM; GENETIC TRANSCRIPTION; GLUCOSE OXIDATION; HUMAN; MELANOMA; METABOLIC REGULATION; METASTASIS; MITOCHONDRIAL BIOGENESIS; MITOCHONDRIAL RESPIRATION; MOLECULARLY TARGETED THERAPY; NONHUMAN; OXIDATIVE PHOSPHORYLATION; OXIDATIVE STRESS; PANCREAS ADENOCARCINOMA; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; REVIEW; SUMOYLATION; TRANSACTIVATION; TUMOR MICROENVIRONMENT; TUMOR RESISTANCE; ANIMAL; CELL TRANSFORMATION; CHEMISTRY; ENERGY METABOLISM; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; NEOPLASMS; SIGNAL TRANSDUCTION; STRUCTURE ACTIVITY RELATION;

ANIMALS; CELL TRANSFORMATION, NEOPLASTIC; ENERGY METABOLISM; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; NEOPLASMS; OXIDATIVE STRESS; PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR GAMMA COACTIVATOR 1-ALPHA; SIGNAL TRANSDUCTION; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84969584358     PISSN: 15357163     EISSN: 15388514     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-15-0621     Document Type: Review

References (119)

1. Boroughs LK, DeBerardinis RJ.Metabolic pathways promoting cancer cell survival and growth. Nat Cell Biol 2015;17:351-9.
2. Ward PS, Thompson CB. Metabolic reprogramming: a cancer hallmark even Warburg did not anticipate. Cancer Cell 2012;21:297-308.
3. Hensley CT, Wasti AT, DeBerardinis RJ. Glutamine and cancer: cell biology, physiology, and clinical opportunities. J Clin Invest 2013;123: 3678-84.
4. Currie E, Schulze A, Zechner R, Walther TC, Farese RVJrCellular fatty acid metabolism and cancer. Cell Metab 2013;18:153-61.
5. Locasale JW. Serine, glycine and one-carbon units: cancer metabolism in full circle. Nat Rev Cancer 2013;13:572-83.
6. Weinberg SE, Chandel NS. Targetingmitochondria metabolismfor cancer therapy. Nat Chem Biol 2015;11:9-15.
7. Seyfried TN, Flores RE, Poff AM, D'Agostino DP. Cancer as a metabolic disease: implications for novel therapeutics. Carcinogenesis 2014;35: 515-27.
8. Bobrovnikova-Marjon E, Hurov JB. Targetingmetabolic changes in cancer: novel therapeutic approaches. Annu Rev Med 2014;65:157-70.
9. Staubert C, Bhuiyan H, Lindahl A, Broom OJ, Zhu Y, IslamS, et al. Rewired metabolism in drug-resistant leukemia cells: a metabolic switch hallmarked by reduced dependence on exogenous glutamine. J Biol Chem 2015;290:8348-59.
10. Jones AW, Yao Z, Vicencio JM, Karkucinska-Wieckowska A, Szabadkai G. PGC-1 family coactivators and cell fate: roles in cancer, neurodegeneration, cardiovascular disease and retrograde mitochondria-nucleus signalling. Mitochondrion 2012;12:86-99.
11. Girnun GD. The diverse role of the PPARgamma coactivator 1 family of transcriptional coactivators in cancer. Semin Cell Dev Biol 2012;23: 381-8.
12. Finck BN, Kelly DP. PGC-1 coactivators: inducible regulators of energy metabolism in health and disease. J Clin Invest 2006;116:615-22.
13. Handschin C, Spiegelman BM. The role of exercise and PGC1alpha in inflammation and chronic disease. Nature 2008;454:463-9.
14. Liu C, Lin JD. PGC-1 coactivators in the control of energy metabolism. Acta Biochim Biophys Sin 2011;43:248-57.
15. Lin J, Handschin C, Spiegelman BM. Metabolic control through the PGC-1 family of transcription coactivators. Cell Metab 2005;1:361-70.
16. Lin J, Wu H, Tarr PT, Zhang CY, Wu Z, Boss O, et al. Transcriptional coactivator PGC-1 alpha drives the formation of slow-twitch muscle fibres. Nature 2002;418:797-801.
17. Handschin C, Rhee J, Lin J, Tarr PT, Spiegelman BM. An autoregulatory loop controls peroxisome proliferator-activated receptor gamma coactivator 1alpha expression in muscle. Proc Natl Acad Sci U S A 2003;100: 7111-6.
18. Patti ME, Butte AJ, Crunkhorn S, Cusi K, Berria R, Kashyap S, et al. Coordinated reduction of genes of oxidative metabolismin humans with insulin resistance and diabetes: Potential role of PGC1 and NRF1. Proc Natl Acad Sci USA 2003;100:8466-71.
19. Mootha VK, Handschin C, Arlow D, Xie X, St Pierre J, Sihag S, et al. Erralpha and Gabpa/b specify PGC-1alpha-dependent oxidative phosphorylation gene expression that is altered in diabetic muscle. Proc Natl Acad Sci USA 2004;101:6570-5.
20. Nemoto S, Fergusson MM, Finkel T. SIRT1 functionally interacts with the metabolic regulator and transcriptional coactivator PGC-1(alpha). J Biol Chem 2005;280:16456-60.
21. Amat R, Planavila A, Chen SL, Iglesias R, Giralt M, Villarroya F. SIRT1 controls the transcription of the peroxisome proliferator-activated receptor-gamma Co-activator-1alpha (PGC-1alpha) gene in skeletal muscle through the PGC-1alpha autoregulatory loop and interactionwith MyoD. J Biol Chem 2009;284:21872-80.
22. Haemmerle G, Moustafa T, Woelkart G, Buttner S, Schmidt A, van de Weijer T, et al. ATGL-mediated fat catabolism regulates cardiac mitochondrial function via PPAR-alpha and PGC-1. Nat Med 2011;17:1076-85.
23. Khan SA, Sathyanarayan A, Mashek MT, Ong KT, Wollaston-Hayden EE, Mashek DG. ATGL-catalyzed lipolysis regulates SIRT1 to control PGC-1alpha/PPAR-alpha signaling. Diabetes 2015;64:418-26.
24. Louet JF, Hayhurst G, Gonzalez FJ, Girard J, Decaux JF. The coactivator PGC-1 is involved in the regulation of the liver carnitine palmitoyltransferase I gene expression by cAMP in combination with HNF4 alpha and cAMP-response element-binding protein (CREB). J Biol Chem 2002;277: 37991-8000.
25. Zhang Y, Ma K, Song S, Elam MB, Cook GA, Park EA. Peroxisomal proliferator-activated receptor-gamma coactivator-1 alpha (PGC-1 alpha) enhances the thyroid hormone induction of carnitine palmitoyltransferase I (CPT-I alpha). J Biol Chem 2004;279:53963-71.
26. La Spada AR. PPARGC1A/PGC-1alpha, TFEB and enhanced proteostasis in Huntington disease: defining regulatory linkages between energy production and protein-organelle quality control. Autophagy 2012;8: 1845-7.
27. Tsunemi T, Ashe TD, Morrison BE, Soriano KR, Au J, Roque RA, et al. PGC-1alpha rescues Huntington's disease proteotoxicity by preventing oxidative stress and promoting TFEB function. Sci TranslMed 2012;4:142ra97.
28. Wu Z, Puigserver P, Andersson U, Zhang C, Adelmant G, Mootha V, et al. Mechanisms controlling mitochondrial biogenesis and respiration through the thermogenic coactivator PGC-1. Cell 1999;98:115-24.
29. Puigserver P,WuZ, Park CW, Graves R, Wright M, Spiegelman BM. A coldinducible coactivator of nuclear receptors linked to adaptive thermogenesis. Cell 1998;92:829-39.
30. Bostrom P, Wu J, Jedrychowski MP, Korde A, Ye L, Lo JC, et al. A PGC1-alpha-dependent myokine that drives brown-fat-like development of white fat and thermogenesis. Nature 2012;481:463-8.
31. Olmos Y, Valle I, Borniquel S, Tierrez A, Soria E, Lamas S, et al. Mutual dependence of Foxo3a and PGC-1alpha in the induction of oxidative stress genes. J Biol Chem 2009;284:14476-84.
32. Abdanipour A, Tiraihi T, Noori-Zadeh A, Majdi A, Gosaili R. Evaluation of lovastatin effects on expression of anti-apoptotic Nrf2 and PGC-1alpha genes in neural stem cells treated with hydrogen peroxide. Mol Neurobiol 2014;49:1364-72.
33. St-Pierre J, Drori S, Uldry M, Silvaggi JM, Rhee J, Jager S, et al. Suppression of reactive oxygen species and neurodegeneration by the PGC-1 transcriptional coactivators. Cell 2006;127:397-408.
34. Austin S, St-Pierre J. PGC1alpha and mitochondrial metabolism-emerging concepts and relevance in ageing and neurodegenerative disorders. J Cell Sci 2012;125:4963-71.
35. Puigserver P.Tissue-specific regulation ofmetabolic pathways through the transcriptional coactivator PGC1-alpha. Int J Obes 2005;29:S5-9.
36. Wolf DA.Is reliance on mitochondrial respiration a "chink in the armor" of therapy-resistant cancer? Cancer Cell 2014;26:788-95.
37. Puigserver P, Adelmant G,Wu Z, Fan M, Xu J,O'Malley B, et al. Activation of PPARgamma coactivator-1 through transcription factor docking. Science 1999;286:1368-71.
38. Puigserver P, Rhee J, Donovan J, Walkey CJ, Yoon JC, Oriente F, et al. Insulin-regulated hepatic gluconeogenesis through FOXO1-PGC-1alpha interaction. Nature 2003;423:550-5.
39. Knutti D, Kaul A, Kralli A. A tissue-specific coactivator of steroid receptors, identified in a functional genetic screen. Mol Cell Biol 2000;20:2411-22.
40. Wallberg AE, Yamamura S, Malik S, Spiegelman BM, Roeder RG. Coordination of p300-mediated chromatin remodeling and TRAP/mediator function through coactivator PGC-1alpha. Mol Cell 2003;12:1137-49.
41. Monsalve M, Wu Z, Adelmant G, Puigserver P, Fan M, Spiegelman BM. Direct coupling of transcription and mRNA processing through the thermogenic coactivator PGC-1. Mol Cell 2000;6:307-16.
42. Jager S, Handschin C, St-Pierre J, Spiegelman BM. AMP-activated protein kinase (AMPK) action in skeletal muscle via direct phosphorylation of PGC-1alpha. Proc Natl Acad Sci U S A 2007;104:12017-22.
43. Rodgers JT, Lerin C, Haas W, Gygi SP, Spiegelman BM, Puigserver P. Nutrient control of glucose homeostasis through a complex of PGC-1alpha and SIRT1. Nature 2005;434:113-8.
44. Knutti D, Kressler D, Kralli A. Regulation of the transcriptional coactivator PGC-1 via MAPK-sensitive interaction with a repressor. Proc Natl Acad Sci U S A 2001;98:9713-8.
45. Li X, Monks B, Ge Q, BirnbaumMJ. Akt/PKB regulates hepatic metabolism by directly inhibiting PGC-1alpha transcription coactivator. Nature 2007;447:1012-6.
46. Rytinki MM, Palvimo JJ. SUMOylation attenuates the function of PGC-1alpha. J Biol Chem 2009;284:26184-93.
47. Herzig S, Long F, Jhala US, Hedrick S, Quinn R, Bauer A, et al. CREB regulates hepatic gluconeogenesis through the coactivator PGC-1. Nature 2001;413:179-83.
48. Bianchi K, Vandecasteele G, Carli C, Romagnoli A, Szabadkai G, Rizzuto R. Regulation of Ca2+ signalling and Ca2+-mediated cell death by the transcriptional coactivator PGC-1alpha. Cell Death Differ 2006;13: 586-96.
49. Bhalla K, Hwang BJ, Dewi RE, Ou L, Twaddel W, Fang HB, et al. PGC1alpha promotes tumor growth by inducing gene expression programs supporting lipogenesis. Cancer Res 2011;71:6888-98.
50. Taguchi A,Delgado O, Celiktas M, KatayamaH,WangH, Gazdar AF, et al. Proteomic signatures associated with p53 mutational status in lung adenocarcinoma. Proteomics 2014;14:2750-9.
51. McGuirk S, Gravel SP, Deblois G, Papadopoli DJ, Faubert B, Wegner A, et al. PGC-1alpha supports glutamine metabolism in breast cancer. Cancer Metab 2013;1:22.
52. Shiota M, Yokomizo A, Tada Y, Inokuchi J, Tatsugami K, Kuroiwa K, et al. Peroxisome proliferator-activated receptor gamma coactivator-1alpha interacts with the androgen receptor (AR) and promotes prostate cancer cell growth by activating the AR. Mol Endocrinol 2010;24:114-27.
53. Vazquez F, Lim JH, Chim H, Bhalla K, Girnun G, Pierce K, et al. PGC1alpha expression defines a subset of human melanoma tumors with increased mitochondrial capacity and resistance to oxidative stress. Cancer Cell 2013;23:287-301.
54. Aquilano K, Baldelli S, Pagliei B, Cannata SM, Rotilio G, Ciriolo MR. p53 orchestrates the PGC-1alpha-mediated antioxidant response upon mild redox and metabolic imbalance. Antioxid Redox Signal 2013; 18:386-99.
55. LaGory EL, Wu C, Taniguchi CM, Ding CK, Chi JT, von Eyben R, et al. Suppression of PGC-1a is critical for reprogramming oxidative metabolism in renal cell carcinoma. Cell Rep 2015;12:116-27.
56. Sancho P, Burgos-Ramos E, Tavera A, Bou Kheir T, Jagust P, Schoenhals M, et al. MYC/PGC-1a balance determines the metabolic phenotype and plasticity of pancreatic cancer stem cells. Cell Metab 2015;22: 590-605.
57. Haq R, Shoag J, Andreu-Perez P, Yokoyama S, Edelman H, Rowe GC, et al. Oncogenic BRAF regulates oxidative metabolism via PGC1alpha and MITF. Cancer Cell 2013;23:302-15.
58. Carracedo A,Weiss D, Leliaert AK, Bhasin M, de Boer VC, Laurent G, et al. A metabolic prosurvival role for PML in breast cancer. J Clin Invest 2012;122:3088-100.
59. Riker AI, Enkemann SA, Fodstad O, Liu S, Ren S, Morris C, et al. The gene expression profiles of primary and metastatic melanoma yields a transition point of tumor progression and metastasis. BMC Med Genomics 2008;1:13.
60. Bogunovic D, O'NeillDW,Belitskaya-Levy I, Vacic V, Yu YL, Adams S, et al. Immune profile and mitotic index of metastatic melanoma lesions enhance clinical staging in predicting patient survival. Proc Natl Acad Sci U S A 2009;106:20429-34.
61. Ronai Z.The masters talk: the PGC-1alpha-MITF axis as a melanoma energizer. Pigment Cell Melanoma Res 2013;26:294-295.
62. Davies H, Bignell GR, Cox C, Stephens P, Edkins S, Clegg S, et al. Mutations of the BRAF gene in human cancer. Nature 2002;417:949-54.
63. Wan PT, Garnett MJ, Roe SM, Lee S, Niculescu-Duvaz D, Good VM, et al. Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF. Cell 2004;116:855-67.
64. Poulikakos PI, Rosen N. Mutant BRAF melanomas-dependence and resistance. Cancer Cell 2011;19:11-5.
65. Hernandez-Davies JE, Tran TQ, Reid MA, Rosales KR, Lowman XH, Pan M, et al. Vemurafenib resistance reprograms melanoma cells towards glutamine dependence. J Transl Med 2015;13:210.
66. Chapman PB, Hauschild A, Robert C, Haanen JB, Ascierto P, Larkin J, et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 2011;364:2507-16.
67. Flaherty KT, Robert C, Hersey P, Nathan P, Garbe C, Milhem M, et al. Improved survival with MEK inhibition in BRAF-mutated melanoma. N Engl J Med 2012;367:107-14.
68. Gopal YN, Rizos H, Chen G, Deng W, Frederick DT, Cooper ZA, et al. Inhibition of mTORC1/2 overcomes resistance to MAPK pathway inhibitors mediated by PGC1a and oxidative phosphorylation inmelanoma. Cancer Res 2014;74:7037-47.
69. Huss JM, Garbacz WG, Xie W. Constitutive activities of estrogen-related receptors: transcriptional regulation of metabolism by the ERR pathways in health and disease. Biochim Biophys Acta 2015;1852:1912-27.
70. Fisher KW, Das B, Kortum RL, Chaika OV, Lewis RE. Kinase suppressor of ras 1 (KSR1) regulates PGC1alpha and estrogen-related receptor alpha to promote oncogenic Ras-dependent anchorage-independent growth. Mol Cell Biol 2011;31:2453-61.
71. Sun RC, Denko NC. Hypoxic regulation of glutamine metabolism through HIF1 and SIAH2 supports lipid synthesis that is necessary for tumor growth. Cell Metab 2014;19:285-92.
72. Klimcakova E, Chenard V, McGuirk S, Germain D, Avizonis D, Muller WJ, et al. PGC-1alpha promotes the growth of ErbB2/Neu-inducedmammary tumors by regulating nutrient supply. Cancer Res 2012;72:1538-46.
73. Arany Z, Foo SY, Ma Y, Ruas JL, Bommi-Reddy A, Girnun G, et al. HIFindependent regulation of VEGF and angiogenesis by the transcriptional coactivator PGC-1alpha. Nature 2008;451:1008-12.
74. Chen EI, Hewel J, Krueger JS, Tiraby C, Weber MR, Kralli A, et al. Adaptation of energy metabolism in breast cancer brain metastases. Cancer Res 2007;67:1472-86.
75. LeBleu VS, O'Connell JT, Gonzalez Herrera KN, Wikman H, Pantel K, Haigis MC, et al. PGC-1alpha mediates mitochondrial biogenesis and oxidative phosphorylation in cancer cells to promotemetastasis. Nat Cell Biol 2014;16:992-1003, 1-15.
76. Deblois G, St-Pierre J, Giguere V. The PGC-1/ERR signaling axis in cancer. Oncogene 2013;32:3483-90.
77. Hsieh AL, Walton ZE, Altman BJ, Stine ZE, Dang CV. MYC and metabolism on the path to cancer. Semin Cell Dev Biol 2015.
78. Stine ZE, Walton ZE, Altman BJ, Hsieh AL, Dang CV. MYC, metabolism, and cancer. Cancer Discov 2015;5:1024-39.
79. Viale A, Pettazzoni P, Lyssiotis CA, Ying H, SanchezN,MarchesiniM, et al. Oncogene ablation-resistant pancreatic cancer cells depend on mitochondrial function. Nature 2014;514:628-32.
80. Samudio I,Harmancey R, FieglM, Kantarjian H, Konopleva M, Korchin B, et al. Pharmacologic inhibition of fatty acid oxidation sensitizes human leukemia cells to apoptosis induction. J Clin Invest 2010;120:142-56.
81. Caro P, Kishan AU, Norberg E, Stanley IA, Chapuy B, Ficarro SB, et al. Metabolic signatures uncover distinct targets in molecular subsets of diffuse large B cell lymphoma. Cancer Cell 2012;22:547-60.
82. Schlaepfer IR, Rider L, Rodrigues LU, Gijon MA, Pac CT, Romero L, et al. Lipid catabolism via CPT1 as a therapeutic target for prostate cancer. Mol Cancer Ther 2014;13:2361-71.
83. Zaugg K, Yao Y, Reilly PT, Kannan K, Kiarash R, Mason J, et al. Carnitine palmitoyltransferase 1C promotes cell survival and tumor growth under conditions of metabolic stress. Genes Dev 2011;25:1041-51.
84. Vega RB, Huss JM, Kelly DP. The coactivator PGC-1 cooperates with peroxisome proliferator-activated receptor alpha in transcriptional control of nuclear genes encoding mitochondrial fatty acid oxidation enzymes. Mol Cell Biol 2000;20:1868-76.
85. Peters JM, Shah YM, Gonzalez FJ. The role of peroxisome proliferatoractivated receptors in carcinogenesis and chemoprevention. Nat Rev Cancer 2012;12:181-95.
86. van't Veer LJ, Dai H, van de Vijver MJ, He YD, Hart AA,MaoM, et al. Gene expression profiling predicts clinical outcome of breast cancer. Nature 2002;415:530-6.
87. Ito K, Carracedo A,Weiss D, Arai F, Ala U, Avigan DE, et al. A PML-PPARdelta pathway for fatty acid oxidation regulates hematopoietic stem cell maintenance. Nat Med 2012;18:1350-8.
88. Gan B, Hu J, Jiang S, Liu Y, Sahin E, Zhuang L, et al. Lkb1 regulates quiescence and metabolic homeostasis of haematopoietic stem cells. Nature 2010;468:701-4.
89. Morrison SJ, Kimble J. Asymmetric and symmetric stem-cell divisions in development and cancer. Nature 2006;441:1068-74.
90. Ito K, Bernardi R, Pandolfi PP. A novel signaling network as a critical rheostat for the biology and maintenance of the normal stem cell and the cancer-initiating cell. Curr Opin Genet Dev 2009;19:51-9.
91. De Luca A, Fiorillo M, Peiris-Pages M, Ozsvari B, Smith DL, Sanchez-Alvarez R, et al. Mitochondrial biogenesis is required for the anchorageindependent survival and propagation of stem-like cancer cells. Oncotarget 2015;6:14777-95.
92. Rahman M, Miyamoto H, Chang C. Androgen receptor coregulators in prostate cancer: mechanisms and clinical implications. Clin Cancer Res 2004;10:2208-19.
93. Massie CE, Lynch A, Ramos-Montoya A, Boren J, Stark R, Fazli L, et al. The androgen receptor fuels prostate cancer by regulating central metabolism and biosynthesis. EMBO J 2011;30:2719-33.
94. Tennakoon JB, Shi Y, Han JJ, Tsouko E, White MA, Burns AR, et al. Androgens regulate prostate cancer cell growth via an AMPK-PGC-1alphamediated metabolic switch. Oncogene 2014;33:5251-61.
95. Smeenk L, Lohrum M. Behind the scenes: unravelling the molecular mechanisms of p53 target gene selectivity (Review). Int J Oncol 2010; 37:1061-70.
96. Sen N, Satija YK, Das S. PGC-1a, a key modulator of p53, promotes cell survival upon metabolic stress. Mol Cell 2011;44:621-34.
97. Cioce M, Blandino G.PGC1a confers specificity-metabolic stress and p53-dependent transcription. Mol Cell 2011;44:515-6.
98. ChenW,WangQ, Bai L, ChenW,Wang X, Tellez CS, et al. RIP1 maintains DNA integrity and cell proliferation by regulating PGC-1a-mediated mitochondrial oxidative phosphorylation and glycolysis. Cell Death Differ 2014;21:1061-70.
99. Chiarugi A, Dolle C, Felici R, Ziegler M. The NAD metabolome - a key determinant of cancer cell biology. Nat Rev Cancer 2012;12: 741-52.
100. Gerhart-Hines Z, Rodgers JT, Bare O, Lerin C, Kim SH, Mostoslavsky R, et al. Metabolic control of muscle mitochondrial function and fatty acid oxidation through SIRT1/PGC-1alpha. EMBO J 2007;26:1913-23.
101. Kulkarni SR, Donepudi AC, Xu J, Wei W, Cheng QC, Driscoll MV, et al. Fasting induces nuclear factor E2-related factor 2 and ATP-binding Cassette transporters via protein kinase A and Sirtuin-1 in mouse and human. Antioxid Redox Signal 2014;20:15-30.
102. DoMT, Kim HG, Choi JH, Jeong HG. Metformin induces microRNA-34a to downregulate the Sirt1/Pgc-1alpha/Nrf2 pathway, leading to increased susceptibility of wild-type p53 cancer cells to oxidative stress and therapeutic agents. Free Radic Biol Med 2014;74:21-34.
103. Sadeghi N, Abbruzzese JL, Yeung SC, Hassan M, Li D. Metformin use is associated with better survival of diabetic patients with pancreatic cancer. Clin Cancer Res 2012;18:2905-12.
104. Dang CV.Links between metabolism and cancer. Genes Dev 2012;26: 877-90.
105. Lim JH, Luo C, Vazquez F, Puigserver P. Targeting mitochondrial oxidative metabolism in melanoma causes metabolic compensation through glucose and glutamine utilization. Cancer Res 2014;74:3535-45.
106. Watkins G, Douglas-Jones A, Mansel RE, Jiang WG. The localisation and reduction of nuclear staining of PPARgamma and PGC-1 in human breast cancer. Oncol Rep 2004;12:483-8.
107. Feilchenfeldt J, Brundler MA, Soravia C, Totsch M, Meier CA. Peroxisome proliferator-activated receptors (PPARs) and associated transcription factors in colon cancer: reduced expression of PPARgamma-coactivator 1 (PGC-1). Cancer Lett 2004;203:25-33.
108. Lee HJ, Su Y, Yin PH, Lee HC, Chi CW. PPAR(gamma)/PGC-1(alpha) pathway in E-cadherin expression and motility ofHepG2 cells. Anticancer Res 2009;29:5057-63.
109. Zhang Y, Ba Y, Liu C, Sun G, Ding L, Gao S, et al. PGC-1alpha induces apoptosis in human epithelial ovarian cancer cells through a PPARgamma-dependent pathway. Cell Res 2007;17:363-73.
110. Jiang WG, Douglas-Jones A, Mansel RE. Expression of peroxisome-proliferator activated receptor-gamma (PPARgamma) and the PPARgamma co-activator, PGC-1, in human breast cancer correlates with clinical outcomes. Int J Cancer 2003;106:752-7.
111. D'Errico I, Salvatore L, Murzilli S, Lo Sasso G, Latorre D, Martelli N, et al. Peroxisome proliferator-activated receptor-gamma coactivator 1-alpha (PGC1alpha) is a metabolic regulator of intestinal epithelial cell fate. Proc Natl Acad Sci U S A 2011;108:6603-8.
112. Neill T, Torres A, Buraschi S, Owens RT, Hoek JB, Baffa R, et al. Decorin induces mitophagy in breast carcinoma cells via peroxisome proliferatoractivated receptor gamma coactivator-1a (PGC-1a) and mitostatin. J Biol Chem 2014;289:4952-68.
113. D'Errico I, Lo Sasso G, Salvatore L, Murzilli S, Martelli N, Cristofaro M, et al. Bax is necessary for PGC1alpha pro-apoptotic effect in colorectal cancer cells. Cell Cycle 2011;10:2937-45.
114. Li X, Lu Y, Lu H, Luo J, Hong Y, Fan Z. AMPK-mediated energy homeostasis and associated metabolic effects on cancer cell response and resistance to cetuximab. Oncotarget 2015;6:11507-18.
115. Zhang JG, Hong DF, Zhang CW, Sun XD, Wang ZF, Shi Y, et al. Sirtuin 1 facilitates chemoresistance of pancreatic cancer cells by regulating adaptive response to chemotherapy-induced stress. Cancer Sci 2014;105: 445-54.
116. Egan DF, Chun MG, Vamos M, Zou H, Rong J, Miller CJ, et al. Small molecule inhibition of the autophagy kinase ULK1 and identification of ULK1 substrates. Mol Cell 2015;59:285-97.
117. Galluzzi L, Pietrocola F, Bravo-San Pedro JM, Amaravadi RK, Baehrecke EH, Cecconi F, et al. Autophagy in malignant transformation and cancer progression. EMBO J 2015;34:856-80.
118. Rodriguez-Enriquez S, Hernandez-Esquivel L, Marin-Hernandez A, El Hafidi M, Gallardo-Perez JC, Hernandez-Resendiz I, et al. Mitochondrial free fatty acid beta-oxidation supports oxidative phosphorylation and proliferation in cancer cells. Int J Biochem Cell Biol 2015;65: 209-21.
119. Hossain F, Al-Khami AA, Wyczechowska D, Hernandez C, Zheng L, Reiss K, et al. Inhibition of fatty acid oxidation modulates immunosuppressive functions of myeloid-derived suppressor cells and enhances cancer therapies. Cancer Immunol Res 2015;3:1236-47.